$heff's $tation of $tocks & $olid DD

[ADVFN_bioking]

BXRX =MC $52 M --FDA Decision in Q1 for a BIG Drug -- unknown low float stock =500%++ UPSIDE .LIFETIME OPP

Janney starts Baudax Bio at buy; fair value estimate $12
https://biotuesdays.com/2019/11/22/janney-starts-baudax-bio-at-buy-fair-value-estimate-12/

Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.
She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”